Autres langues Medivir AB Deutsche Boerse AG

Actions

MVR0

SE0020181014

Temps Différé Deutsche Boerse AG Autres places de cotation 09:57:50 17/07/2024			Varia. 5j.	Varia. 1 janv.
0,22 ^EUR	-3,51 %		-11,65 %	+0,55 %

27/06	Medivir AB présente de nouvelles données positives de son étude de phase Ib / IIa en cours sur la fostroxacitabine bralpamide (Fostrox) + Lenvima® dans le carcinome hépatocellulaire avancé (CHC)	CI
19/06	Medivir sélectionne un partenaire CRO mondial pour la prochaine étude de phase 2B sur le CHC avec fostrox + Lenvima et initie la faisabilité de l'étude	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Number of shares and votes in Medivir AB on 28 June 2024	28/06
BioStock: Medivir presents promising results in difficult-to-treat patient population	27/06
Medivir : Presentation	27/06
Fostrox + Lenvima® holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GI	27/06
Medivir AB Presents Positive New Data from Its Ongoing Phase Ib / IIa Study of Fostroxacitabine Bralpamide + Lenvima® in Advanced Hepatocellular Carcinoma	27/06
Certain Shares of Medivir AB are subject to a Lock-Up Agreement Ending on 20-JUN-2024.	20/06
Medivir selects global CRO partner for upcoming phase 2b study in HCC with fostrox + Lenvima and initiates study feasibility	19/06
Medivir Selects Global CRO Partner for Upcoming Phase 2B Study in HCC with fostrox + Lenvima and Initiates Study Feasibility	19/06
Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2024	30/05
Medivir to present at Redeye Growth Day	30/05
Medivir : acute;s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program	23/05
Medivir's licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program	23/05
Resolutions at the Annual General Meeting in Medivir on 7 May 2024	07/05
Medivir Aktiebolag Approves Board Appointments	07/05
BioStock: Double thumbs up for Medivir from the FDA	03/05
MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2024	30/04
Medivir AB Reports Earnings Results for the First Quarter Ended March 31, 2024	30/04
Medivir brings the Q1 webcast forward to 10 a.m. on April 30	29/04
Medivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GI	29/04
Medivir AB Provides Update from Positive Type C Meeting with the FDA; Preparations for Enhanced Phase 2b in HCC with Fostrox + Lenvima	29/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Medivir AB Deutsche Boerse AG

Actions

MVR0

SE0020181014

Autres langues

Filtres